Member of the Board of Directors, Corporate Development, Partnering
Christian Mauriand was elected to the Board of Directors of InnoMedica in 2025. He was responsible for building Roivant Sciences HQ in Basel, where he last served as Global Head of Corporate Development. He participated in over USD 11 billion worth of transactions, including Roche's acquisition of Telavant and Organon's acquisition of Dermavant. He also co-founded the software developer iRewind, which was later sold to Yoveo.
Christian Mauriand completed his studies in Business Administration at the University of St. Gallen. He has been a representative of the Swiss Private Equity & Corporate Finance Association (SECA) and President of SECA Romandie since 2016.
